Albemarle Reports Third Quarter Results

 
 

ALBemarle Corporation (NYSE: ALB) today announced its results for the third quarter ended September 30, 2020 .

 
 

  Albemarle Corp. Logo. (PRNewsFoto/Albemarle Corporation) 

 
 

  Third Quarter 2020 Highlights
  (Unless otherwise stated, all percent changes are based on year-over-year comparisons)  

 
  • Net income of $98 million , or $0.92 per diluted share; Adjusted diluted EPS of $1.09  
  •  
  • Net sales of $747 million decreased by 15%, in-line with Q3 2020 outlook
  •  
  • Adjusted EBITDA of $216 million decreased by 15%, exceeding the high-end of Q3 2020 outlook by 14%
  •  
  • Our plants continue to operate without material impact from the COVID-19 pandemic
  •  
  • Increased cost savings: approximately $80 million of sustainable cost savings to be achieved in 2020
  •  
  • Maintained our quarterly dividend of $0.385 per share, an increase of approximately 5% over the quarterly dividend paid in 2019
  •  

"  Albemarle  reported another solid quarter with Q3 2020 net sales in the upper end of our outlook range and adjusted EBITDA exceeding outlook. Our performance was driven by operating teams committed to running our businesses safely and efficiently in the face of pandemic-related economic weakness, and to our successful sustainable cost savings initiative," said Albemarle CEO Kent Masters . "We now expect to realize approximately $80 million of cost savings this year and to reach an annual savings rate of $120 million or more by the end of 2021. We expect these savings to represent a first wave of ongoing operational improvements that will reap notable benefits for the company."

 

  Outlook  

 

  Albemarle anticipates that its full year 2020 performance will be lower year-over-year based on reduced global economic activity due to the global pandemic.

 
 
              
 
 

   FY 2020 Outlook   

 
 

  Net sales  

 
 

  $3.05 - $3.15 billion  

 
 

  Adjusted EBITDA  

 
 

  $780 - $810 million  

 
 

  Adjusted EBITDA Margin  

 
 

  25% - 26%  

 
 

  Adj. Diluted EPS  

 
 

  $3.80 - $4.15  

 
 

  Net Cash from Operations  

 
 

  $660 - $710 million  

 
 

  Capital Expenditures  

 
 

  $850 - $900 million  

 
 
 

  COVID-19 Response  

 

  Albemarle's cross-functional Global Response Team continues to meet biweekly to assess the situation and take necessary actions to address employee health and safety and operational challenges. Our first priority is always the health and well-being of our employees, customers, and communities. Beyond that, our focus has shifted from managing an immediate crisis to building in the flexibility needed to adjust for regional differences and changing conditions. Protocols including restricted travel, shift adjustments, increased hygiene, and social distancing for the essential workers at our plants remain in place at all locations. In some regions, employees are able to return to their work sites. Other regions, including most of North and South America , remain on work-from-home protocols for non-essential personnel.

 

  Third Quarter Results  

 
 
                                                                                                       
 

   In millions, except per share amounts   

 
 

   Q3 2020   

 
 
 

   Q3 2019   

 
 
 

   $ Change   

 
 
 

   % Change   

 
 

  Net sales  

 
 

  $  

 
 

  746.9  

 
 
 
 

  $  

 
 

  879.7  

 
 
 
 

  $  

 
 

  (132.9)  

 
 
 
 

  (15.1)  

 
 

  %  

 
 

  Net income attributable to Albemarle Corporation  

 
 

  $  

 
 

  98.3  

 
 
 
 

  $  

 
 

  155.1  

 
 
 
 

  $  

 
 

  (56.8)  

 
 
 
 

  (36.6)  

 
 

  %  

 
 

  Adjusted EBITDA (a)  

 
 

  $  

 
 

  216.1  

 
 
 
 

  $  

 
 

  254.4  

 
 
 
 

  $  

 
 

  (38.3)  

 
 
 
 

  (15.1)  

 
 

  %  

 
 

  Diluted earnings per share  

 
 

  $  

 
 

  0.92  

 
 
 
 

  $  

 
 

  1.46  

 
 
 
 

  $  

 
 

  (0.54)  

 
 
 
 

  (37.0)  

 
 

  %  

 
 

  Non-operating pension and OPEB items (a)  

 
 

  (0.02)  

 
 
 
 

  (0.01)  

 
 
 
 
 
 
 

  Non-recurring and other unusual items (a)  

 
 

  0.19  

 
 
 
 

  0.08  

 
 
 
 
 
 
 

  Adjusted diluted earnings per share (b)  

 
 

  $  

 
 

  1.09  

 
 
 
 

  $  

 
 

  1.53  

 
 
 
 

  $  

 
 

  (0.44)  

 
 
 
 

  (28.8)  

 
 

  %  

 
 
 
 
      
 
 
 

  (a)  

 
 

  See Non-GAAP Reconciliations for further details.  

 
 

  (b)  

 
 

  Totals may not add due to rounding.  

 
 
 

Net sales of $746.9 million decreased by $132.9 million compared to the prior year quarter, primarily driven by the Catalysts and Lithium business segments as discussed below.

 

Adjusted EBITDA of $216.1 million decreased by $38.3 million from the prior year quarter due to lower net sales, which were partially offset by productivity and cost improvements. Similarly, net income attributable to Albemarle of $98.3 million decreased by $56.8 million from the prior year. Corporate costs including SG&A were down compared to the prior year period as a result of cost savings initiatives.

 

We have increased our sustainable cost savings and now expect to achieve approximately $80 million of sustainable savings in 2020, up from previous estimates of $50 to $70 million . We now expect these savings to reach a run-rate of more than $120 million by year-end 2021, up from previous estimates of more than $100 million . We continue to take short-term cash management measures and delay capital expenditures. Short-term savings are expected to average approximately $25 to $40 million per quarter. Full-year 2020 capital spending is now expected to be approximately $850 to $900 million .

 

The effective income tax rate for Q3 2020 was 25.2% compared to 15.5% in the same period in 2019. The difference is largely due to a change in the geographic mix of earnings and foreign uncertain tax positions and foreign return to accrual adjustments recorded in Q3 2020. On an adjusted basis, the effective income tax rates were 16.7% and 15.0% for the third quarter of 2020 and 2019, respectively.

 

  Business Segment Results  

 

  Lithium  

 
 
                                      
 

   In millions   

 
 

   Q3 2020   

 
 
 

   Q3 2019   

 
 
 

   $ Change   

 
 
 

   % Change   

 
 

  Net Sales  

 
 

  $  

 
 

  265.6  

 
 
 
 

  $  

 
 

  330.4  

 
 
 
 

  $  

 
 

  (64.7)  

 
 
 
 

  (19.6)  

 
 

  %  

 
 

  Adjusted EBITDA  

 
 

  $  

 
 

  97.8  

 
 
 
 

  $  

 
 

  127.5  

 
 
 
 

  $  

 
 

  (29.7)  

 
 
 
 

  (23.3)  

 
 

  %  

 
 
 

Lithium net sales of $265.6 million declined $64.7 million primarily due to lower contract and market pricing. Lower contract pricing reflects 2020 battery-grade price adjustments that were agreed to in late 2019. Adjusted EBITDA of $97.8 million declined by $29.7 million primarily due to reduced net sales as well as reduced Talison equity income. The decline was partially offset by cost savings initiatives and efficiency improvements.

 

   Current Trends:   We expect Q4 2020 adjusted EBITDA to be up between 10% and 20% compared to Q3 2020 as customers continue to meet planned volume commitments for FY 2020. We anticipate FY 2021 volumes to be relatively flat as plants are effectively sold out given volume constraints. Our Kemerton and La Negra expansion projects are expected to be commissioned in 2021 with sales volume beginning in 2022. FY 2021 pricing is expected to be down slightly primarily due to lower average realized pricing for carbonate and technical grade products.

 

  Bromine Specialties  

 
 
                                      
 

   In millions   

 
 

   Q3 2020   

 
 
 

   Q3 2019   

 
 
 

   $ Change   

 
 
 

   % Change   

 
 

  Net Sales  

 
 

  $  

 
 

  237.2  

 
 
 
 

  $  

 
 

  256.3  

 
 
 
 

  $  

 
 

  (19.1)  

 
 
 
 

  (7.4)  

 
 

  %  

 
 

  Adjusted EBITDA  

 
 

  $  

 
 

  79.4  

 
 
 
 

  $  

 
 

  88.8  

 
 
 
 

  $  

 
 

  (9.4)  

 
 
 
 

  (10.5)  

 
 

  %  

 
 
 

Bromine net sales of $237.2 million declined $19.1 million primarily due to lower volumes driven by the recent economic downturn related to the COVID-19 pandemic. Adjusted EBITDA of $79.4 million declined $9.4 million due to lower net sales, partially offset by cost savings initiatives.

 

   Current Trends:   We expect Q4 2020 adjusted EBITDA to be similar to Q3 2020. Stabilization in electronics and building and construction helps offset weakness in other end use markets. We expect FY 2021 results to improve slightly assuming continued economic recovery and on-going cost savings initiatives.

 

  Catalysts  

 
 
                                      
 

   In millions   

 
 

   Q3 2020   

 
 
 

   Q3 2019   

 
 
 

   $ Change   

 
 
 

   % Change   

 
 

  Net Sales  

 
 

  $  

 
 

  197.9  

 
 
 
 

  $  

 
 

  261.3  

 
 
 
 

  $  

 
 

  (63.4)  

 
 
 
 

  (24.3)  

 
 

  %  

 
 

  Adjusted EBITDA  

 
 

  $  

 
 

  37.8  

 
 
 
 

  $  

 
 

  66.9  

 
 
 
 

  $  

 
 

  (29.1)  

 
 
 
 

  (43.5)  

 
 

  %  

 
 
 

Catalysts net sales of $197.9 million declined $63.4 million due primarily to lower volumes. Fluid Catalytic Cracking (FCC) volume improved sequentially, but remains below prior year due to lower transportation fuel consumption as a result of travel restrictions. Hydroprocessing Catalysts (HPC) volume was also down compared to the prior year due to normal lumpiness of shipments and softness related to lower oil prices and reduced fuel demand. Adjusted EBITDA of $37.8 million declined $29.1 million as a result of lower net sales offset by cost savings initiatives and efficiency improvements.

 

   Current Trends:   We expect Q4 2020 adjusted EBITDA to be down between 20% and 30% sequentially due to HPC volume and mix. FCC demand is expected to continue to gradually recover in line with increased travel and depletion of global gasoline inventories. HPC demand tends to be lumpier than FCC demand and is also expected to continue to be negatively impacted as refiners defer spending into 2021 and 2022. We expect FY 2021 results to continue to improve from the very low levels seen in FY 2020, but to remain well below pre-COVID demand levels, assuming a slow recovery of refinery capacity utilization and margins.

 

  All Other  

 
 
                                      
 

   In millions   

 
 

   Q3 2020   

 
 
 

   Q3 2019   

 
 
 

   $ Change   

 
 
 

   % Change   

 
 

  Net Sales  

 
 

  $  

 
 

  46.1  

 
 
 
 

  $  

 
 

  31.7  

 
 
 
 

  $  

 
 

  14.4  

 
 
 
 

  45.2  

 
 

  %  

 
 

  Adjusted EBITDA  

 
 

  $  

 
 

  25.0  

 
 
 
 

  $  

 
 

  10.4  

 
 
 
 

  $  

 
 

  14.5  

 
 
 
 

  139.1  

 
 

  %  

 
 
 

Other operations represents our Fine Chemistry Services (FCS) business. FCS net sales of $46.1 million increased $14.4 million and adjusted EBITDA of $25.0 million increased $14.5 million . The FCS business tends to be contract driven. Recent contracts include life sciences products which are typically anti-cyclical.

 

  Balance Sheet and Liquidity  

 

As of September 30, 2020 , Albemarle had estimated liquidity of over $1.5 billion , including $702 million of cash and equivalents, $610 million remaining under our $1 billion revolver, and $223 million on other available credit lines. Total debt was $3.5 billion , representing net debt to adjusted EBITDA of approximately 3.2 times.

 

  Cash Flow and Capital Deployment  

 

Cash from operations for the nine months ended September 30, 2020 , of $461.7 million , increased $116.1 million versus the prior year as reduced working capital outflows and cost savings more than offset lower revenues. Capital expenditures of $621.4 million were in-line with the prior year as progress continued on our Lithium expansion projects.

 

Our primary capital allocation priorities are to maintain our investment grade rating and our quarterly dividend, while preserving our long-term growth profile.

 

In October, the board declared a quarterly dividend of $0.385 per share, an increase of approximately 5% over the quarterly dividend paid in 2019. We expect 2020 to be our 26th consecutive year of dividend increase, and the company remains committed to shareholder returns.

 

Our share repurchase authorization remains in place; however, there are no near-term plans to execute share buybacks. Divestiture activity is proceeding despite on-going travel restrictions.

 

  Earnings Call  

 
 
          
 

  Date:  

 
 

  Thursday, November 5, 2020  

 
 

  Time:  

 
 

  9:00 AM Eastern time  

 
 

  Dial-in (U.S.):  

 
 

  844-347-1034  

 
 

  Dial-in (International):  

 
 

  209-905-5910  

 
 

  Passcode:  

 
 

  6829479  

 
 
 

The Company's earnings presentation and supporting material are available on Albemarle's website at https://investors.albemarle.com .

 

  About Albemarle   

 

 ALBemarle Corporation (NYSE: ALB), headquartered in Charlotte, N.C. , is a global specialty chemicals company with leading positions in lithium, bromine and refining catalysts. We think beyond business-as-usual to power the potential of companies in many of the world's largest and most critical industries, such as energy, electronics, and transportation. We actively pursue a sustainable approach to managing our diverse global footprint of world-class resources. In conjunction with our highly experienced and talented global teams, our deep-seated values, and our collaborative customer relationships, we create value-added and performance-based solutions that enable a safer and more sustainable future.

 

We regularly post information to www.albemarle.com , including notification of events, news, financial performance, investor presentations and webcasts, non-GAAP reconciliations, SEC filings and other information regarding our company, its businesses and the markets it serves.

 

  Forward-Looking Statements  

 

Some of the information presented in this press release, the conference call and discussions that follow, including, without limitation, information related to product development, production capacity, committed volumes, market trends, pricing, expected growth, earnings and demand for our products, input costs, surcharges, tax rates, stock repurchases, dividends, cash flow generation, costs and cost synergies, capital projects, economic trends, outlook and all other information relating to matters that are not historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the views expressed. Factors that could cause actual results to differ materially from the outlook expressed or implied in any forward-looking statement include, without limitation: changes in economic and business conditions; changes in financial and operating performance of our major customers and industries and markets served by us; the timing of orders received from customers; the gain or loss of significant customers; competition from other manufacturers; changes in the demand for our products or the end-user markets in which our products are sold; limitations or prohibitions on the manufacture and sale of our products; availability of raw materials; increases in the cost of raw materials and energy, and our ability to pass through such increases to our customers; changes in our markets in general; fluctuations in foreign currencies; changes in laws and government regulation impacting our operations or our products; the occurrence of regulatory actions, proceedings, claims or litigation; the occurrence of cyber-security breaches, terrorist attacks, industrial accidents, natural disasters or climate change; the inability to maintain current levels of product or premises liability insurance or the denial of such coverage; political unrest affecting the global economy, including adverse effects from terrorism or hostilities; political instability affecting our manufacturing operations or joint ventures; changes in accounting standards; the inability to achieve results from our global manufacturing cost reduction initiatives as well as our ongoing continuous improvement and rationalization programs; changes in the jurisdictional mix of our earnings and changes in tax laws and rates; changes in monetary policies, inflation or interest rates that may impact our ability to raise capital or increase our cost of funds, impact the performance of our pension fund investments and increase our pension expense and funding obligations; volatility and uncertainties in the debt and equity markets; technology or intellectual property infringement, including cyber-security breaches, and other innovation risks; decisions we may make in the future; the ability to successfully execute, operate and integrate acquisitions and divestitures; uncertainties as to the duration and impact of the coronavirus (COVID-19) pandemic; and the other factors detailed from time to time in the reports we file with the SEC, including those described under "Risk Factors" in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release. We assume no obligation to provide any revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

 

Albemarle Corporation and Subsidiaries
Consolidated Statements of Income
(In Thousands Except Per Share Amounts) (Unaudited)

 
 
                                                                                                                                                                                                                                                                            
 
 

   Three Months Ended   

 
 
 

   Nine Months Ended   

 
 
 

   September 30,   

 
 
 

   September 30,   

 
 
 

   2020   

 
 
 

   2019   

 
 
 

   2020   

 
 
 

   2019   

 
 

   Net sales   

 
 

  $  

 
 

  746,868  

 
 
 
 

  $  

 
 

  879,747  

 
 
 
 

  $  

 
 

  2,249,762  

 
 
 
 

  $  

 
 

  2,596,863  

 
 
 

  Cost of goods sold  

 
 

  492,812  

 
 
 
 

  569,880  

 
 
 
 

  1,520,329  

 
 
 
 

  1,677,596  

 
 
 

   Gross profit   

 
 

  254,056  

 
 
 
 

  309,867  

 
 
 
 

  729,433  

 
 
 
 

  919,267  

 
 
 

  Selling, general and administrative expenses  

 
 

  96,092  

 
 
 
 

  108,135  

 
 
 
 

  304,918  

 
 
 
 

  348,205  

 
 
 

  Research and development expenses  

 
 

  13,532  

 
 
 
 

  15,585  

 
 
 
 

  43,839  

 
 
 
 

  44,024  

 
 
 

   Operating profit   

 
 

  144,432  

 
 
 
 

  186,147  

 
 
 
 

  380,676  

 
 
 
 

  527,038  

 
 
 

  Interest and financing expenses  

 
 

  (19,227)  

 
 
 
 

  (11,108)  

 
 
 
 

  (53,964)  

 
 
 
 

  (35,295)  

 
 
 

  Other expenses, net  

 
 

  (3,661)  

 
 
 
 

  (11,316)  

 
 
 
 

  (1,620)  

 
 
 
 

  (7,090)  

 
 
 

  Income before income taxes and equity in net income of unconsolidated investments  

 
 

  121,544  

 
 
 
 

  163,723  

 
 
 
 

  325,092  

 
 
 
 

  484,653  

 
 
 

  Income tax expense  

 
 

  30,653  

 
 
 
 

  25,341  

 
 
 
 

  64,526  

 
 
 
 

  93,266  

 
 
 

  Income before equity in net income of unconsolidated investments  

 
 

  90,891  

 
 
 
 

  138,382  

 
 
 
 

  260,566  

 
 
 
 

  391,387  

 
 
 

  Equity in net income of unconsolidated investments (net of tax)  

 
 

  26,154  

 
 
 
 

  33,236  

 
 
 
 

  83,872  

 
 
 
 

  106,727  

 
 
 

  Net income  

 
 

  117,045  

 
 
 
 

  171,618  

 
 
 
 

  344,438  

 
 
 
 

  498,114  

 
 
 

  Net income attributable to noncontrolling interests  

 
 

  (18,744)  

 
 
 
 

  (16,548)  

 
 
 
 

  (53,309)  

 
 
 
 

  (55,277)  

 
 
 

  Net income attributable to Albemarle Corporation  

 
 

  $  

 
 

  98,301  

 
 
 
 

  $  

 
 

  155,070  

 
 
 
 

  $  

 
 

  291,129  

 
 
 
 

  $  

 
 

  442,837  

 
 
 

  Basic earnings per share  

 
 

  $  

 
 

  0.92  

 
 
 
 

  $  

 
 

  1.46  

 
 
 
 

  $  

 
 

  2.74  

 
 
 
 

  $  

 
 

  4.18  

 
 
 

  Diluted earnings per share  

 
 

  $  

 
 

  0.92  

 
 
 
 

  $  

 
 

  1.46  

 
 
 
 

  $  

 
 

  2.73  

 
 
 
 

  $  

 
 

  4.16  

 
 
 
 
 
 
 
 
 
 
 

  Weighted-average common shares outstanding – basic  

 
 

  106,386  

 
 
 
 

  105,999  

 
 
 
 

  106,314  

 
 
 
 

  105,920  

 
 
 

  Weighted-average common shares outstanding – diluted  

 
 

  106,873  

 
 
 
 

  106,299  

 
 
 
 

  106,640  

 
 
 
 

  106,324  

 
 
 
 

Albemarle Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(In Thousands) (Unaudited)

 
 
                                                                                                                                                                                                                                                  
 
 

   September 30,   

 
 
 

   December 31,   

 
 
 

   2020   

 
 
 

   2019   

 
 

   ASSETS   

 
 
 
 
 

  Current assets:  

 
 
 
 
 

  Cash and cash equivalents  

 
 

  $  

 
 

  702,073  

 
 
 
 

  $  

 
 

  613,110  

 
 
 

  Trade accounts receivable  

 
 

  516,166  

 
 
 
 

  612,651  

 
 
 

  Other accounts receivable  

 
 

  61,522  

 
 
 
 

  67,551  

 
 
 

  Inventories  

 
 

  828,080  

 
 
 
 

  768,984  

 
 
 

  Other current assets  

 
 

  119,171  

 
 
 
 

  162,813  

 
 
 

  Total current assets  

 
 

  2,227,012  

 
 
 
 

  2,225,109  

 
 
 

  Property, plant and equipment  

 
 

  7,284,575  

 
 
 
 

  6,817,843  

 
 
 

  Less accumulated depreciation and amortization  

 
 

  2,041,851  

 
 
 
 

  1,908,370  

 
 
 

  Net property, plant and equipment  

 
 

  5,242,724  

 
 
 
 

  4,909,473  

 
 
 

  Investments  

 
 

  603,745  

 
 
 
 

  579,813  

 
 
 

  Other assets  

 
 

  211,534  

 
 
 
 

  213,061  

 
 
 

  Goodwill  

 
 

  1,603,049  

 
 
 
 

  1,578,785  

 
 
 

  Other intangibles, net of amortization  

 
 

  343,919  

 
 
 
 

  354,622  

 
 
 

  Total assets  

 
 

  $  

 
 

  10,231,983  

 
 
 
 

  $  

 
 

  9,860,863  

 
 
 

   LIABILITIES AND EQUITY   

 
 
 
 
 

  Current liabilities:  

 
 
 
 
 

  Accounts payable  

 
 

  $  

 
 

  465,644  

 
 
 
 

  $  

 
 

  574,138  

 
 
 

  Accrued expenses  

 
 

  477,510  

 
 
 
 

  576,297  

 
 
 

  Current portion of long-term debt  

 
 

  603,787  

 
 
 
 

  187,336  

 
 
 

  Dividends payable  

 
 

  40,787  

 
 
 
 

  38,764  

 
 
 

  Income taxes payable  

 
 

  25,011  

 
 
 
 

  32,461  

 
 
 

  Total current liabilities  

 
 

  1,612,739  

 
 
 
 

  1,408,996  

 
 
 

  Long-term debt  

 
 

  2,940,533  

 
 
 
 

  2,862,921  

 
 
 

  Postretirement benefits  

 
 

  49,926  

 
 
 
 

  50,899  

 
 
 

  Pension benefits  

 
 

  285,942  

 
 
 
 

  292,073  

 
 
 

  Other noncurrent liabilities  

 
 

  612,013  

 
 
 
 

  754,536  

 
 
 

  Deferred income taxes  

 
 

  405,449  

 
 
 
 

  397,858  

 
 
 

  Commitments and contingencies  

 
 
 
 
 

  Equity:  

 
 
 
 
 

  Albemarle Corporation shareholders' equity:  

 
 
 
 
 

  Common stock  

 
 

  1,065  

 
 
 
 

  1,061  

 
 
 

  Additional paid-in capital  

 
 

  1,410,534  

 
 
 
 

  1,383,446  

 
 
 

  Accumulated other comprehensive loss  

 
 

  (398,467)  

 
 
 
 

  (395,735)  

 
 
 

  Retained earnings  

 
 

  3,111,749  

 
 
 
 

  2,943,478  

 
 
 

  Total Albemarle Corporation shareholders' equity  

 
 

  4,124,881  

 
 
 
 

  3,932,250  

 
 
 

  Noncontrolling interests  

 
 

  200,500  

 
 
 
 

  161,330  

 
 
 

  Total equity  

 
 

  4,325,381  

 
 
 
 

  4,093,580  

 
 
 

  Total liabilities and equity  

 
 

  $  

 
 

  10,231,983  

 
 
 
 

  $  

 
 

  9,860,863  

 
 
 
 

Albemarle Corporation and Subsidiaries
Selected Consolidated Cash Flow Data
(In Thousands) (Unaudited)

 
 
                                                                                                                                                                                                                                
 
 

   Nine Months Ended
  September 30,  
 

 
 
 

   2020   

 
 
 

   2019   

 
 

  Cash and cash equivalents at beginning of year  

 
 

  $  

 
 

  613,110  

 
 
 
 

  $  

 
 

  555,320  

 
 
 

  Cash flows from operating activities:  

 
 
 
 
 

  Net income  

 
 

  344,438  

 
 
 
 

  498,114  

 
 
 

  Adjustments to reconcile net income to cash flows from operating activities:  

 
 
 
 
 

  Depreciation and amortization  

 
 

  170,214  

 
 
 
 

  156,718  

 
 
 

  Gain on sale of property  

 
 

  

 
 
 
 

  (11,079)  

 
 
 

  Stock-based compensation and other  

 
 

  15,864  

 
 
 
 

  15,169  

 
 
 

  Equity in net income of unconsolidated investments (net of tax)  

 
 

  (83,872)  

 
 
 
 

  (106,727)  

 
 
 

  Dividends received from unconsolidated investments and nonmarketable securities  

 
 

  61,309  

 
 
 
 

  62,982  

 
 
 

  Pension and postretirement (benefit) expense  

 
 

  (4,975)  

 
 
 
 

  1,641  

 
 
 

  Pension and postretirement contributions  

 
 

  (10,323)  

 
 
 
 

  (10,728)  

 
 
 

  Unrealized gain on investments in marketable securities  

 
 

  (3,377)  

 
 
 
 

  (1,701)  

 
 
 

  Deferred income taxes  

 
 

  7,920  

 
 
 
 

  7,726  

 
 
 

  Working capital changes  

 
 

  (167,436)  

 
 
 
 

  (289,587)  

 
 
 

  Other, net  

 
 

  131,952  

 
 
 
 

  23,110  

 
 
 

  Net cash provided by operating activities  

 
 

  461,714  

 
 
 
 

  345,638  

 
 
 

  Cash flows from investing activities:  

 
 
 
 
 

  Acquisitions, net of cash acquired  

 
 

  (22,572)  

 
 
 
 

  

 
 
 

  Capital expenditures  

 
 

  (621,371)  

 
 
 
 

  (608,456)  

 
 
 

  Proceeds from sale of property and equipment  

 
 

  

 
 
 
 

  10,356  

 
 
 

  Sales of marketable securities, net  

 
 

  1,208  

 
 
 
 

  1,177  

 
 
 

  Investments in equity and other corporate investments  

 
 

  (786)  

 
 
 
 

  (2,569)  

 
 
 

  Net cash used in investing activities  

 
 

  (643,521)  

 
 
 
 

  (599,492)  

 
 
 

  Cash flows from financing activities:  

 
 
 
 
 

  Repayments of borrowings from credit agreements  

 
 

  (250,000)  

 
 
 
 

  

 
 
 

  Proceeds from borrowings of credit agreements  

 
 

  452,163  

 
 
 
 

  

 
 
 

  Other borrowings, net  

 
 

  202,786  

 
 
 
 

  232,183  

 
 
 

  Dividends paid to shareholders  

 
 

  (120,836)  

 
 
 
 

  (113,321)  

 
 
 

  Dividends paid to noncontrolling interests  

 
 

  (14,286)  

 
 
 
 

  (57,212)  

 
 
 

  Proceeds from exercise of stock options  

 
 

  16,925  

 
 
 
 

  4,814  

 
 
 

  Withholding taxes paid on stock-based compensation award distributions  

 
 

  (4,803)  

 
 
 
 

  (10,774)  

 
 
 

  Debt financing costs  

 
 

  (2,751)  

 
 
 
 

  

 
 
 

  Other  

 
 

  

 
 
 
 

  (445)  

 
 
 

  Net cash provided by financing activities  

 
 

  279,198  

 
 
 
 

  55,245  

 
 
 

  Net effect of foreign exchange on cash and cash equivalents  

 
 

  (8,428)  

 
 
 
 

  (38,888)  

 
 
 

  Increase (decrease) in cash and cash equivalents  

 
 

  88,963  

 
 
 
 

  (237,497)  

 
 
 

  Cash and cash equivalents at end of period  

 
 

  $  

 
 

  702,073  

 
 
 
 

  $  

 
 

  317,823  

 
 
 
 

Albemarle Corporation and Subsidiaries
Consolidated Summary of Segment Results
(In Thousands) (Unaudited)

 
 
                                                                                                                                                                                            
 
 

   Three Months Ended   

 
 
 

   Nine Months Ended   

 
 
 

   September 30,   

 
 
 

   September 30,   

 
 
 

   2020   

 
 
 

   2019   

 
 
 

   2020   

 
 
 

   2019   

 
 

   Net sales:   

 
 
 
 
 
 
 
 
 

  Lithium  

 
 

  $  

 
 

  265,646  

 
 
 
 

  $  

 
 

  330,386  

 
 
 
 

  $  

 
 

  786,186  

 
 
 
 

  $  

 
 

  947,030  

 
 
 

  Bromine Specialties  

 
 

  237,193  

 
 
 
 

  256,267  

 
 
 
 

  701,564  

 
 
 
 

  760,752  

 
 
 

  Catalysts  

 
 

  197,919  

 
 
 
 

  261,346  

 
 
 
 

  602,179  

 
 
 
 

  779,295  

 
 
 

  All Other  

 
 

  46,110  

 
 
 
 

  31,748  

 
 
 
 

  159,833  

 
 
 
 

  109,786  

 
 
 

  Total net sales  

 
 

  $  

 
 

  746,868  

 
 
 
 

  $  

 
 

  879,747  

 
 
 
 

  $  

 
 

  2,249,762  

 
 
 
 

  $  

 
 

  2,596,863  

 
 
 
 
 
 
 
 
 
 
 

   Adjusted EBITDA:   

 
 
 
 
 
 
 
 
 

  Lithium  

 
 

  $  

 
 

  97,789  

 
 
 
 

  $  

 
 

  127,459  

 
 
 
 

  $  

 
 

  270,962  

 
 
 
 

  $  

 
 

  384,854  

 
 
 

  Bromine Specialties  

 
 

  79,448  

 
 
 
 

  88,814  

 
 
 
 

  235,751  

 
 
 
 

  248,743  

 
 
 

  Catalysts  

 
 

  37,834  

 
 
 
 

  66,944  

 
 
 
 

  108,081  

 
 
 
 

  193,890  

 
 
 

  All Other  

 
 

  24,985  

 
 
 
 

  10,448  

 
 
 
 

  66,407  

 
 
 
 

  28,931  

 
 
 

  Corporate  

 
 

  (24,001)  

 
 
 
 

  (39,314)  

 
 
 
 

  (83,588)  

 
 
 
 

  (114,300)  

 
 
 

  Total adjusted EBITDA  

 
 

  $  

 
 

  216,055  

 
 
 
 

  $  

 
 

  254,351  

 
 
 
 

  $  

 
 

  597,613  

 
 
 
 

  $  

 
 

  742,118  

 
 
 
 

See accompanying non-GAAP reconciliations below.

 

  Additional Information  

 

It should be noted that adjusted net income attributable to Albemarle Corporation, adjusted diluted earnings per share, non-operating pension and OPEB items per diluted share, non-recurring and other unusual items per diluted share, adjusted effective income tax rates, EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin are financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in the United States , or GAAP. These non-GAAP measures should not be considered as alternatives to Net income attributable to Albemarle Corporation ("earnings"). These measures are presented here to provide additional useful measurements to review our operations, provide transparency to investors and enable period-to-period comparability of financial performance. The Company's chief operating decision maker uses these measures to assess the ongoing performance of the Company and its segments, as well as for business and enterprise planning purposes.

 

A description of other non-GAAP financial measures that we use to evaluate our operations and financial performance, and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP can be found on the following pages of this press release, which is also is available on Albemarle's website at https://investors.albemarle.com . The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, as the Company is unable to estimate significant non-recurring or unusual items without unreasonable effort. The amounts and timing of these items are uncertain and could be material to the Company's results calculated in accordance with GAAP.

 

   ALBEMARLE CORPORATION AND SUBSIDIARIES  

 

  Non-GAAP Reconciliations  

 

  (Unaudited)  

 

See below for a reconciliation of adjusted net income attributable to Albemarle Corporation, EBITDA and adjusted EBITDA, the non-GAAP financial measures, to Net income attributable to Albemarle Corporation ("earnings"), the most directly comparable financial measure calculated and reported in accordance with GAAP. Adjusted earnings is defined as earnings before the non-recurring, other unusual and non-operating pension and OPEB items as listed below. EBITDA is defined as earnings before interest and financing expenses, income taxes, and depreciation and amortization. Adjusted EBITDA is defined as EBITDA and the non-recurring, other unusual and non-operating pension and OPEB items as listed below.

 
 
                                                                                                                                                                                                                                                                                                    
 
 

   Three Months Ended   

 
 
 

   Nine Months Ended   

 
 
 

   September 30,   

 
 
 

   September 30,   

 
 

   In thousands, except percentages and per share amounts   

 
 

   2020   

 
 
 

   2019   

 
 
 

   2020   

 
 
 

   2019   

 
 

  Net income attributable to Albemarle Corporation  

 
 

  $  

 
 

  98,301  

 
 
 
 

  $  

 
 

  155,070  

 
 
 
 

  $  

 
 

  291,129  

 
 
 
 

  $  

 
 

  442,837  

 
 
 

  Add back:  

 
 
 
 
 
 
 
 
 

  Non-operating pension and OPEB items (net of tax)  

 
 

  (2,294)  

 
 
 
 

  (543)  

 
 
 
 

  (6,904)  

 
 
 
 

  (1,805)  

 
 
 

  Non-recurring and other unusual items (net of tax)  

 
 

  20,278  

 
 
 
 

  8,497  

 
 
 
 

  29,678  

 
 
 
 

  17,239  

 
 
 

  Adjusted net income attributable to Albemarle Corporation  

 
 

  $  

 
 

  116,285  

 
 
 
 

  $  

 
 

  163,024  

 
 
 
 

  $  

 
 

  313,903  

 
 
 
 

  $  

 
 

  458,271  

 
 
 
 
 
 
 
 
 
 
 

  Adjusted diluted earnings per share  

 
 

  $  

 
 

  1.09  

 
 
 
 

  $  

 
 

  1.53  

 
 
 
 

  $  

 
 

  2.94  

 
 
 
 

  $  

 
 

  4.31  

 
 
 
 
 
 
 
 
 
 
 

  Weighted-average common shares outstanding – diluted  

 
 

  106,873  

 
 
 
 

  106,299  

 
 
 
 

  106,640  

 
 
 
 

  106,324  

 
 
 
 
 
 
 
 
 
 
 

  Net income attributable to Albemarle Corporation  

 
 

  $  

 
 

  98,301  

 
 
 
 

  $  

 
 

  155,070  

 
 
 
 

  $  

 
 

  291,129  

 
 
 
 

  $  

 
 

  442,837  

 
 
 

  Add back:  

 
 
 
 
 
 
 
 
 

  Interest and financing expenses  

 
 

  19,227  

 
 
 
 

  11,108  

 
 
 
 

  53,964  

 
 
 
 

  35,295  

 
 
 

  Income tax expense  

 
 

  30,653  

 
 
 
 

  25,341  

 
 
 
 

  64,526  

 
 
 
 

  93,266  

 
 
 

  Depreciation and amortization  

 
 

  58,679  

 
 
 
 

  54,487  

 
 
 
 

  170,214  

 
 
 
 

  156,718  

 
 
 

   EBITDA   

 
 

  206,860  

 
 
 
 

  246,006  

 
 
 
 

  579,833  

 
 
 
 

  728,116  

 
 
 

  Non-operating pension and OPEB items  

 
 

  (2,901)  

 
 
 
 

  (551)  

 
 
 
 

  (8,704)  

 
 
 
 

  (1,810)  

 
 
 

  Non-recurring and other unusual items  

 
 

  12,096  

 
 
 
 

  8,896  

 
 
 
 

  26,484  

 
 
 
 

  15,812  

 
 
 

   Adjusted EBITDA   

 
 

  $  

 
 

  216,055  

 
 
 
 

  $  

 
 

  254,351  

 
 
 
 

  $  

 
 

  597,613  

 
 
 
 

  $  

 
 

  742,118  

 
 
 
 
 
 
 
 
 
 
 

  Net sales  

 
 

  $  

 
 

  746,868  

 
 
 
 

  $  

 
 

  879,747  

 
 
 
 

  $  

 
 

  2,249,762  

 
 
 
 

  $  

 
 

  2,596,863  

 
 
 

  EBITDA margin  

 
 

  27.7  

 
 

  %  

 
 
 

  28.0  

 
 

  %  

 
 
 

  25.8  

 
 

  %  

 
 
 

  28.0  

 
 

  %  

 
 

  Adjusted EBITDA margin  

 
 

  28.9  

 
 

  %  

 
 
 

  28.9  

 
 

  %  

 
 
 

  26.6  

 
 

  %  

 
 
 

  28.6  

 
 

  %  

 
 
 

See below for a reconciliation of adjusted EBITDA on a segment basis, the non-GAAP financial measure, to Net income attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in accordance with GAAP (in thousands, except percentages).

 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
 
 

   Lithium   

 
 
 

   Bromine Specialties   

 
 
 

   Catalysts   

 
 
 

   Reportable Segments Total   

 
 
 

   All Other   

 
 
 

   Corporate   

 
 
 

   Consolidated Total   

 
 
 

   % of Net Sales   

 
 

   Three months ended September 30, 2020   

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Net income (loss) attributable to Albemarle Corporation  

 
 

  $  

 
 

  69,102  

 
 
 
 

  $  

 
 

  66,548  

 
 
 
 

  $  

 
 

  25,176  

 
 
 
 

  $  

 
 

  160,826  

 
 
 
 

  $  

 
 

  22,798  

 
 
 
 

  $  

 
 

  (85,323)  

 
 
 
 

  $  

 
 

  98,301  

 
 
 
 

  13.2  

 
 

  %  

 
 

  Depreciation and amortization  

 
 

  28,687  

 
 
 
 

  12,900  

 
 
 
 

  12,658  

 
 
 
 

  54,245  

 
 
 
 

  2,187  

 
 
 
 

  2,247  

 
 
 
 

  58,679  

 
 
 
 

  7.9  

 
 

  %  

 
 

  Non-recurring and other unusual items  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  12,096  

 
 
 
 

  12,096  

 
 
 
 

  1.6  

 
 

  %  

 
 

  Interest and financing expenses  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  19,227  

 
 
 
 

  19,227  

 
 
 
 

  2.6  

 
 

  %  

 
 

  Income tax expense  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  30,653  

 
 
 
 

  30,653  

 
 
 
 

  4.1  

 
 

  %  

 
 

  Non-operating pension and OPEB items  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  (2,901)  

 
 
 
 

  (2,901)  

 
 
 
 

  (0.4)  

 
 

  %  

 
 

   Adjusted EBITDA   

 
 

  $  

 
 

  97,789  

 
 
 
 

  $  

 
 

  79,448  

 
 
 
 

  $  

 
 

  37,834  

 
 
 
 

  $  

 
 

  215,071  

 
 
 
 

  $  

 
 

  24,985  

 
 
 
 

  $  

 
 

  (24,001)  

 
 
 
 

  $  

 
 

  216,055  

 
 
 
 

  28.9  

 
 

  %  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

   Three months ended September 30, 2019   

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Net income (loss) attributable to Albemarle Corporation  

 
 

  $  

 
 

  102,136  

 
 
 
 

  $  

 
 

  75,224  

 
 
 
 

  $  

 
 

  54,345  

 
 
 
 

  $  

 
 

  231,705  

 
 
 
 

  $  

 
 

  8,305  

 
 
 
 

  $  

 
 

  (84,940)  

 
 
 
 

  $  

 
 

  155,070  

 
 
 
 

  17.6  

 
 

  %  

 
 

  Depreciation and amortization  

 
 

  25,212  

 
 
 
 

  12,448  

 
 
 
 

  12,599  

 
 
 
 

  50,259  

 
 
 
 

  2,143  

 
 
 
 

  2,085  

 
 
 
 

  54,487  

 
 
 
 

  6.2  

 
 

  %  

 
 

  Non-recurring and other unusual items  

 
 

  111  

 
 
 
 

  1,142  

 
 
 
 

  

 
 
 
 

  1,253  

 
 
 
 

  

 
 
 
 

  7,643  

 
 
 
 

  8,896  

 
 
 
 

  1.0  

 
 

  %  

 
 

  Interest and financing expenses  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  11,108  

 
 
 
 

  11,108  

 
 
 
 

  1.3  

 
 

  %  

 
 

  Income tax expense  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  25,341  

 
 
 
 

  25,341  

 
 
 
 

  2.9  

 
 

  %  

 
 

  Non-operating pension and OPEB items  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  (551)  

 
 
 
 

  (551)  

 
 
 
 

  (0.1)  

 
 

  %  

 
 

   Adjusted EBITDA   

 
 

  $  

 
 

  127,459  

 
 
 
 

  $  

 
 

  88,814  

 
 
 
 

  $  

 
 

  66,944  

 
 
 
 

  $  

 
 

  283,217  

 
 
 
 

  $  

 
 

  10,448  

 
 
 
 

  $  

 
 

  (39,314)  

 
 
 
 

  $  

 
 

  254,351  

 
 
 
 

  28.9  

 
 

  %  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

   Nine months ended September 30, 2020   

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Net income (loss) attributable to Albemarle Corporation  

 
 

  $  

 
 

  188,380  

 
 
 
 

  $  

 
 

  198,905  

 
 
 
 

  $  

 
 

  70,770  

 
 
 
 

  $  

 
 

  458,055  

 
 
 
 

  $  

 
 

  60,069  

 
 
 
 

  $  

 
 

  (226,995)  

 
 
 
 

  $  

 
 

  291,129  

 
 
 
 

  12.9  

 
 

  %  

 
 

  Depreciation and amortization  

 
 

  82,582  

 
 
 
 

  36,846  

 
 
 
 

  37,311  

 
 
 
 

  156,739  

 
 
 
 

  6,338  

 
 
 
 

  7,137  

 
 
 
 

  170,214  

 
 
 
 

  7.6  

 
 

  %  

 
 

  Non-recurring and other unusual items  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  26,484  

 
 
 
 

  26,484  

 
 
 
 

  1.2  

 
 

  %  

 
 

  Interest and financing expenses  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  53,964  

 
 
 
 

  53,964  

 
 
 
 

  2.4  

 
 

  %  

 
 

  Income tax expense  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  64,526  

 
 
 
 

  64,526  

 
 
 
 

  2.9  

 
 

  %  

 
 

  Non-operating pension and OPEB items  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  (8,704)  

 
 
 
 

  (8,704)  

 
 
 
 

  (0.4)  

 
 

  %  

 
 

   Adjusted EBITDA   

 
 

  $  

 
 

  270,962  

 
 
 
 

  $  

 
 

  235,751  

 
 
 
 

  $  

 
 

  108,081  

 
 
 
 

  $  

 
 

  614,794  

 
 
 
 

  $  

 
 

  66,407  

 
 
 
 

  $  

 
 

  (83,588)  

 
 
 
 

  $  

 
 

  597,613  

 
 
 
 

  26.6  

 
 

  %  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

   Nine months ended September 30, 2019   

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Net income (loss) attributable to Albemarle Corporation  

 
 

  $  

 
 

  312,609  

 
 
 
 

  $  

 
 

  212,320  

 
 
 
 

  $  

 
 

  156,328  

 
 
 
 

  $  

 
 

  681,257  

 
 
 
 

  $  

 
 

  22,629  

 
 
 
 

  $  

 
 

  (261,049)  

 
 
 
 

  $  

 
 

  442,837  

 
 
 
 

  17.1  

 
 

  %  

 
 

  Depreciation and amortization  

 
 

  71,669  

 
 
 
 

  35,281  

 
 
 
 

  37,562  

 
 
 
 

  144,512  

 
 
 
 

  6,302  

 
 
 
 

  5,904  

 
 
 
 

  156,718  

 
 
 
 

  6.0  

 
 

  %  

 
 

  Non-recurring and other unusual items  

 
 

  576  

 
 
 
 

  1,142  

 
 
 
 

  

 
 
 
 

  1,718  

 
 
 
 

  

 
 
 
 

  14,094  

 
 
 
 

  15,812  

 
 
 
 

  0.6  

 
 

  %  

 
 

  Interest and financing expenses  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  35,295  

 
 
 
 

  35,295  

 
 
 
 

  1.4  

 
 

  %  

 
 

  Income tax expense  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  93,266  

 
 
 
 

  93,266  

 
 
 
 

  3.6  

 
 

  %  

 
 

  Non-operating pension and OPEB items  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  (1,810)  

 
 
 
 

  (1,810)  

 
 
 
 

  (0.1)  

 
 

  %  

 
 

   Adjusted EBITDA   

 
 

  $  

 
 

  384,854  

 
 
 
 

  $  

 
 

  248,743  

 
 
 
 

  $  

 
 

  193,890  

 
 
 
 

  $  

 
 

  827,487  

 
 
 
 

  $  

 
 

  28,931  

 
 
 
 

  $  

 
 

  (114,300)  

 
 
 
 

  $  

 
 

  742,118  

 
 
 
 

  28.6  

 
 

  %  

 
 
 

Non-operating pension and OPEB items, consisting of mark-to-market actuarial gains/losses, settlements/curtailments, interest cost and expected return on assets, are not allocated to our operating segments and are included in the Corporate category. In addition, we believe that these components of pension cost are mainly driven by market performance, and we manage these separately from the operational performance of our businesses. In accordance with GAAP, these non-operating pension and OPEB items are included in Other (expenses) income, net. Non-operating pension and OPEB items were as follows (in thousands):

 
 
                                                            
 
 

   Three Months Ended   

 
 
 

   Nine Months Ended   

 
 
 

   September 30,   

 
 
 

   September 30,   

 
 
 

   2020   

 
 
 

   2019   

 
 
 

   2020   

 
 
 

   2019   

 
 

  Interest cost  

 
 

  $  

 
 

  7,164  

 
 
 
 

  $  

 
 

  8,863  

 
 
 
 

  $  

 
 

  21,452  

 
 
 
 

  $  

 
 

  26,501  

 
 
 

  Expected return on assets  

 
 

  (10,065)  

 
 
 
 

  (9,414)  

 
 
 
 

  (30,156)  

 
 
 
 

  (28,311)  

 
 
 

  Total  

 
 

  $  

 
 

  (2,901)  

 
 
 
 

  $  

 
 

  (551)  

 
 
 
 

  $  

 
 

  (8,704)  

 
 
 
 

  $  

 
 

  (1,810)  

 
 
 
 

In addition to the non-operating pension and OPEB items disclosed above, we have identified certain other items and excluded them from our adjusted net income calculation for the periods presented. A listing of these items, as well as a detailed description of each follows below (per diluted share):

 
 
                                                                                                
 
 

   Three Months Ended   

 
 
 

   Nine Months Ended   

 
 
 

   September 30,   

 
 
 

   September 30,   

 
 
 

   2020   

 
 
 

   2019   

 
 
 

   2020   

 
 
 

   2019   

 
 

  Restructuring and other (1)  

 
 

  $  

 
 

  0.02  

 
 
 
 

  $  

 
 

  

 
 
 
 

  $  

 
 

  0.08  

 
 
 
 

  $  

 
 

  0.05  

 
 
 

  Acquisition and integration related costs (2)  

 
 

  0.04  

 
 
 
 

  0.03  

 
 
 
 

  0.10  

 
 
 
 

  0.10  

 
 
 

  Gain on sale of property (3)  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  (0.08)  

 
 
 

  Other (4)  

 
 

  0.02  

 
 
 
 

  0.05  

 
 
 
 

  0.01  

 
 
 
 

  0.07  

 
 
 

  Discrete tax items (5)  

 
 

  0.11  

 
 
 
 

  

 
 
 
 

  0.09  

 
 
 
 

  0.02  

 
 
 

  Total non-recurring and other unusual items  

 
 

  $  

 
 

  0.19  

 
 
 
 

  $  

 
 

  0.08  

 
 
 
 

  $  

 
 

  0.28  

 
 
 
 

  $  

 
 

  0.16  

 
 
 
 

 

 
 
                                                                          
 

  (1)  

 
 

  In 2020, we recorded severance expenses as part of business reorganization plans, impacting each of our businesses and Corporate, primarily in the U.S., Germany and with our Jordanian joint venture partner. During the three months ended September 30, 2020, we recorded $2.3 million ($1.7 million after income taxes, or $0.02 per share) of severance expenses in Selling, general and administrative expenses. During the nine months ended September 30, 2020, we recorded severance expenses in Cost of goods sold, Selling, general and administrative expenses and Net income attributable to noncontrolling interest of $0.7 million, $10.4 million and a $0.3 million gain ($7.9 million after income taxes, or $0.08 per share), respectively. The balance of unpaid severance is recorded in Accrued expenses and is expected to primarily be paid through 2021. During the nine months ended September 30, 2019, severance expenses of  $5.3 million ($4.9 million after income taxes, or $0.05 per share) were recorded in Selling, general and administrative expenses as part of a business reorganization plan primarily in Catalysts, Lithium and Corporate.  

 
 
 
 

  (2)  

 
 

  Costs related to the acquisition, integration and potential divestitures for various significant projects, recorded in Selling, general and administrative expenses for the three and nine months ended September 30, 2020 of $5.9 million and $14.3 million ($4.6 million and $11.1 million after income taxes, or $0.04 and $0.10 per share), respectively, and for the three and nine months ended September 30, 2019 of $4.1 million and $14.4 million ($3.2 million and $11.1 million after income taxes, or $0.03 and $0.10 per share), respectively.  

 
 
 
 

  (3)  

 
 

  Included in Other (expenses) income, net, for the nine months ended September 30, 2019 is a gain of $11.1 million ($8.5 million after income taxes, or $0.08 per share) related to the sale of land in Pasadena, Texas not used as part of our operations.  

 
 
 
 

  (4)  

 
 

  Other adjustments for the three months ended September 30, 2020 included amounts recorded in:  

 
 
 

  

 
 

  Selling, general and administrative expenses - $3.8 million of a net expense primarily relating to the increase of environmental reserves at at non-operating businesses we have previously divested.  

 
 
 

  

 
 

  Other (expenses) income, net - $0.2 million loss resulting from the settlement of a historical legal matter of an acquired company.  

 
 
 

  After income taxes, these charges totaled $2.7 million, or $0.02 per share.  

 
 
 
 
 

  Other adjustments for the nine months ended September 30, 2020 included amounts recorded in:  

 
 
 

  

 
 

  Selling, general and administrative expenses - $3.8 million of a net expense primarily relating to the increase of environmental reserves at sites that we are no longer operating and are in the process of sellin.  

 
 
 

  

 
 

  Other expenses, net - $2.5 million net gain resulting from the settlement of legal matters related to a business sold or a site in the process of being sold, and $0.8 million net gain primarily relating to the sale of idle properties in Germany, partially offset by a $0.8 million loss resulting from the adjustment of indemnifications related to previously disposed businesses.  

 
 
 

  After income taxes, these charges totaled $1.0 million, or $0.01 per share.  

 
 
 
 
 

  Other adjustments for the three months ended September 30, 2019 included amounts recorded in:  

 
 
 

  

 
 

  Cost of goods sold - $0.1 million related to non-routine labor and compensation related costs in Chile that were outside normal compensation arrangements.  

 
 
 

  

 
 

  Selling, general and administrative expenses - $1.1 million of a write-off of uncollectable accounts receivable from a terminated distributor in the Bromine Specialties segment.  

 
 
 

  

 
 

  Other expenses, net - $3.1 million of unrecoverable vendor costs outside the operations of the business related to the construction of the future Kemerton production facility, as well as a net loss of $0.4 million primarily resulting from the settlement of legal matters related to previously disposed businesses or recorded in purchase accounting.  

 
 
 

  After income taxes, these charges totaled $5.4 million, or $0.05 per share.  

 
 
 
 
 

  Other adjustments for the nine months ended September 30, 2019 included amounts recorded in:  

 
 
 

  

 
 

  Cost of goods sold - $0.6 million related to non-routine labor and compensation related costs in Chile that were outside normal compensation arrangements.  

 
 
 

  

 
 

  Selling, general and administrative expenses - $1.0 million of shortfall contributions for our multiemployer plan financial improvement plan and $1.1 million of a write-off of uncollectable accounts receivable from a terminated distributor in the Bromine Specialities segment.  

 
 
 

  

 
 

  Other expenses, net - $3.1 million of unrecoverable vendor costs outside the operations of the business related to the construction of the future Kemerton production facility, a net loss of $0.4 million primarily resulting from the settlement of legal matters related to previously disposed businesses or recorded in purchase accounting, and $0.9 million of a net loss primarily resulting from the revision of indemnifications and other liabilities related to previously disposed businesses.  

 
 
 

  After income taxes, these charges totaled $7.4 million or $0.07 per share.  

 
 
 
 

  (5)  

 
 

  Included in Income tax expense for the three and nine months ended September 30, 2020 are discrete net tax expenses of $11.3 million, or $0.11 per share, and $9.7 million, or $0.09 per share, respectively. The net expense for the three months is primarily related to expenses for foreign uncertain tax positions and foreign return to accrual adjustments. The net expense for the nine months is primarily related to expenses for foreign uncertain tax positions and foreign return to accrual adjustments, partially offset by a benefit for excess tax benefits realized from stock-based compensation arrangements.  

 
 
 
 
 

  Included in Income tax expense for the nine months ended September 30, 2019 are discrete net tax expenses of $2.3 million, or $0.02 per share. This net expense is primarily related to expenses for uncertain tax positions and foreign return to accrual adjustments, partially offset by a benefit for excess tax benefits realized from stock-based compensation arrangements.  

 
 
 

  See below for a reconciliation of the adjusted effective income tax rate, the non-GAAP financial measure, to the effective income tax rate, the most directly comparable financial measure calculated and reported in accordance with GAAP (in thousands, except percentages).  

 
 
 

 

 
 
                                                                                                                                                                        
 
 

   Income before income taxes and equity in net income of unconsolidated investments   

 
 
 

   Income tax expense   

 
 
 

   Effective income tax rate   

 
 

   Three months ended September 30, 2020   

 
 
 
 
 
 
 

  As reported  

 
 

  $  

 
 

  121,544  

 
 
 
 

  $  

 
 

  30,653  

 
 
 
 

  25.2  

 
 

  %  

 
 

  Non-recurring, other unusual and non-operating pension and OPEB items  

 
 

  9,195  

 
 
 
 

  (8,789)  

 
 
 
 
 

  As adjusted  

 
 

  $  

 
 

  130,739  

 
 
 
 

  $  

 
 

  21,864  

 
 
 
 

  16.7  

 
 

  %  

 
 
 
 
 
 
 
 

   Three months ended September 30, 2019   

 
 
 
 
 
 
 

  As reported  

 
 

  $  

 
 

  163,723  

 
 
 
 

  $  

 
 

  25,341  

 
 
 
 

  15.5  

 
 

  %  

 
 

  Non-recurring, other unusual and non-operating pension and OPEB items  

 
 

  8,345  

 
 
 
 

  391  

 
 
 
 
 

  As adjusted  

 
 

  $  

 
 

  172,068  

 
 
 
 

  $  

 
 

  25,732  

 
 
 
 

  15.0  

 
 

  %  

 
 
 
 
 
 
 
 

   Nine months ended September 30, 2020   

 
 
 
 
 
 
 

  As reported  

 
 

  $  

 
 

  325,092  

 
 
 
 

  $  

 
 

  64,526  

 
 
 
 

  19.8  

 
 

  %  

 
 

  Non-recurring, other unusual and non-operating pension and OPEB items  

 
 

  18,101  

 
 
 
 

  (4,994)  

 
 
 
 
 

  As adjusted  

 
 

  $  

 
 

  343,193  

 
 
 
 

  $  

 
 

  59,532  

 
 
 
 

  17.4  

 
 

  %  

 
 
 
 
 
 
 
 

   Nine months ended September 30, 2019   

 
 
 
 
 
 
 

  As reported  

 
 

  $  

 
 

  484,653  

 
 
 
 

  $  

 
 

  93,266  

 
 
 
 

  19.2  

 
 

  %  

 
 

  Non-recurring, other unusual and non-operating pension and OPEB items  

 
 

  14,002  

 
 
 
 

  (1,432)  

 
 
 
 
 

  As adjusted  

 
 

  $  

 
 

  498,655  

 
 
 
 

  $  

 
 

  91,834  

 
 
 
 

  18.4  

 
 

  %  

 
 
 

 

 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/albemarle-reports-third-quarter-results-301166593.html  

 

SOURCE Albemarle Corporation

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Digital hexagons overlay construction site with an excavator and cloudy sky in the background.

Ekin Ober on Why AI Could Be Mining’s Most Valuable Tool Yet

For Ekin Ober, bringing generative artificial intelligence (AI) to the critical metals sector through her work at Aethos Labs wasn’t just about technological innovation — it reshaped how she thinks about strategy and sustainability in mining.

Now a principal at Kinterra Capital, Ober applies that broad, cross-disciplinary lens to investment decisions, emphasizing the importance of digital fluency, stakeholder alignment and long-term viability.

Her experience helps her identify operational bottlenecks and social license challenges early — essential in guiding assets like nickel and copper projects from concept to production.

Keep reading...Show less
Stacks of US$100 bills with upward-pointing wooden arrows.

Chris Berry: The West Must Invest in Refinement Now or Fall Further Behind

China’s grip on the battery metals sector has drawn increasing scrutiny in recent years as nations confront growing concerns around supply chain risk and resource security.

Through a blend of domestic output and aggressive overseas investment, particularly in Africa and South America, Chinese companies now command a significant share of upstream supply.

The country is responsible for roughly 60 percent of global rare earths production and controls over 70 percent of cobalt supply through its stakes in mines across the Democratic Republic of Congo.

Keep reading...Show less
Magnifying glass focusing on the Albemarle website logo.

Albemarle's Commitment to Sustainability Shines in New Report

As global demand for critical minerals intensifies, Albemarle (NYSE:ALB) continues to position itself as a global leader not only in lithium production but also in sustainable practices.

In its newly released 2024 sustainability report, titled “Values-Led, Purpose-Driven,” the company underscores its commitment to reducing its environmental footprint across six continents, supporting global supply chains and promoting human rights across operations.

From cutting freshwater intensity at its Chilean operations by 28 percent to procuring 24 percent of its electricity from renewable sources, Albemarle is striving to grow its energy storage business while keeping carbon emissions flat, as it translates ESG goals into action.

Keep reading...Show less
Metallic battery with a world map etched on it, against a dark background.

3 Key Themes from Fastmarkets' 2025 Lithium Supply & Battery Raw Materials Event

Market volatility, Chinese control, supply chain risk mitigation and financing emerged as some of the most prevalent themes at the 2025 Fastmarket’s Lithium Supply Battery Raw Materials (LBRM) conference in Las Vegas.

The event, which is in its 17th year, drew a crowd of roughly 1000 delegates, industry experts and analysts, to discuss the current landscape and future projections of the battery materials sector.

During his opening remarks, Fastmarkets CEO Raju Daswani highlighted the growth and maturation the battery raw materials sector has experienced.

Keep reading...Show less
Metals Australia (ASX:MLS)

Metals Australia


Keep reading...Show less

Latest Press Releases

Related News

×